<DOC>
	<DOCNO>NCT00454051</DOCNO>
	<brief_summary>The aim study evaluate expression IgE high affinity receptor ( part cell associate allergic response ) patient suffer uncontrolled severe asthma despite long term treatment high dose inhale corticosteroid long act Beta-2 agonist .</brief_summary>
	<brief_title>Effect Omalizumab Expression IgE Receptors Adults With Severe , Inadequately Controlled Allergic Asthma</brief_title>
	<detailed_description>Double blind placebo control study ass expression IgE blood basophil dendritic cell patient uncontrolled , severe , persistent allergic asthma 16-week Omalizumab treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Adults age &gt; = 18 year . Patients severe persistent allergic asthma follow characteristic : FEV1 ( Forced Expiratory Volume One Second ) &lt; 80 % predict . Frequent daily symptom ( &gt; =4 days/week average ) nocturnal awakening ( &gt; =1/week average ) . Multiple severe asthma exacerbation : either &gt; =2 severe asthma exacerbation require unscheduled medical intervention systemic corticosteroid past year , hospitalization ( include emergency room treatment ) asthma exacerbation past year . Despite high dose inhale corticosteroid &gt; 1000 mg beclomethasone dipropionate equivalent inhale longacting B2agonist . With allergy perennial allergen demonstrate convince criterion , i.e . positive prick skin test vitro reactivity perennial aeroallergen ( RAST ) . Total serum IgE level &gt; = 30 &lt; =700 IU/ml suitable serum total IgE level weight accord Xolair dose tablet . Age &lt; 18 year . Smoking history &gt; 20 pack year . Patients asthma exacerbation 4 week prior randomization History food drug relate severe anaphylactoid anaphylactic reaction Elevated serum IgE level reason allergy ( e.g . parasite infection , hyperimmunoglobulin E syndrome , WiskottAldrich Syndrome allergic bronchopulmonary aspergillosis ) . Patients active cancer , suspicion cancer history cancer . Pregnant woman . Known hypersensitivity omalizumab one component . Patients already treat omalizumab ( indeed previous treatment omalizumab could modify FceRI expression ) . Patients participate clinical trial past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Asthma , anti-immunoglobulin E , omalizumab , IgE receptor</keyword>
</DOC>